CL2007002879A1 - Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer. - Google Patents

Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.

Info

Publication number: CL2007002879A1
Authority: CL; Chile
Prior art keywords: nectina; understands; produces; pharmaceutical composition; monoclonal antibody
Prior art date: 2007-04-04

Application number

CL200702879A

Other languages

English (en)

Inventor

Sato Tsutomu Oshima Tomo Shuji

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-04

Filing date

2007-10-05

Publication date

2008-06-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44083820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002879(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-04 Priority claimed from ARP070101453A external-priority patent/AR060362A1/es

2007-10-05 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2008-06-27 Publication of CL2007002879A1 publication Critical patent/CL2007002879A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Pregnancy & Childbirth (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Gynecology & Obstetrics (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CL200702879A 2007-04-04 2007-10-05 Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer. CL2007002879A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ARP070101453A AR060362A1 (es)	2005-10-07	2007-04-04	Agente para prevenir / tratar el cancer
JP2007100876		2007-04-06

Publications (1)

Publication Number	Publication Date
CL2007002879A1 true CL2007002879A1 (es)	2008-06-27

Family

ID=44083820

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702879A CL2007002879A1 (es)	2007-04-04	2007-10-05	Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.

Country Status (21)

Country	Link
US (1)	US20100008928A1 (es)
EP (1)	EP2067791A4 (es)
JP (1)	JPWO2008044754A1 (es)
KR (1)	KR20090078339A (es)
CN (1)	CN101541834A (es)
AR (1)	AR063153A1 (es)
AU (1)	AU2007307536A1 (es)
BR (1)	BRPI0717024A2 (es)
CA (1)	CA2666249A1 (es)
CL (1)	CL2007002879A1 (es)
CO (1)	CO6190538A2 (es)
EC (1)	ECSP099276A (es)
IL (1)	IL197389A0 (es)
MA (1)	MA30816B1 (es)
MX (1)	MX2009003126A (es)
NO (1)	NO20091783L (es)
PE (1)	PE20081456A1 (es)
RU (1)	RU2009117237A (es)
TN (1)	TN2009000090A1 (es)
TW (1)	TW200823235A (es)
WO (1)	WO2008044754A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012092374A2 (en) *	2010-12-31	2012-07-05	Short Jay M	Express humanization of antibodies
DK2740794T3 (en) *	2011-08-04	2018-06-14	Toray Industries	PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
EP3202419A1 (en) *	2012-06-06	2017-08-09	OncoMed Pharmaceuticals, Inc.	Pvrig binding agents that modulate the hippo pathway and uses thereof
WO2014069682A1 (ko) *	2012-10-29	2014-05-08	인제대학교 산학협력단	암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2014069681A1 (ko) *	2012-10-29	2014-05-08	인제대학교 산학협력단	암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2016134335A2 (en)	2015-02-19	2016-08-25	Compugen Ltd.	Pvrig polypeptides and methods of treatment
PL3653221T3 (pl)	2015-02-19	2022-12-19	Compugen Ltd.	Przeciwciała anty-pvrig i sposoby ich zastosowania
JO3620B1 (ar) *	2015-08-05	2020-08-27	Amgen Res Munich Gmbh	مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
KR102585976B1 (ko)	2016-08-17	2023-10-05	컴퓨젠 엘티디.	항-tigit 항체, 항-pvrig 항체 및 이들의 조합
RU2765410C2 (ru)	2016-11-30	2022-01-28	Онкомед Фармасьютикалс, Инк.	Способы лечения рака, включающие связывающие tigit агенты
US11225523B2 (en)	2017-06-01	2022-01-18	Compugen Ltd.	Triple combination antibody therapies
AU2019306628B2 (en)	2018-07-20	2024-11-14	Surface Oncology, LLC	Anti-CD112R compositions and methods
CN118878685A (zh) *	2019-01-13	2024-11-01	耶路撒冷希伯来大学伊森姆研究发展有限公司	特异性针对人类连接蛋白-2的抗体
CN113527486B (zh) *	2020-04-21	2025-12-02	迈威(上海)生物科技股份有限公司	一种抗Nectin-4的抗体及其应用
BR112023014128A2 (pt)	2021-01-15	2023-10-31	Seagen Inc	Conjugados de anticorpo-fármaco imunomodulatórios
JP2024506300A (ja)	2021-02-03	2024-02-13	シージェンインコーポレイテッド	免疫刺激化合物及びコンジュゲート体
WO2023161943A1 (en) *	2022-02-28	2023-08-31	Nectin Therapeutics Ltd.	Humanized antibodies against nectin-2 and drug conjugates thereof
CA3252067A1 (en)	2022-05-06	2023-11-09	Seagen Inc.	Immunomodulatory Antibody-Drug Conjugates
CA3262320A1 (en)	2022-08-03	2024-02-08	Regents Of The University Of Minnesota	Anti-PD-L1 Conjugates - Immunostimulating Drugs
EP4321522A1 (en)	2022-08-12	2024-02-14	Seagen Inc.	Cytotoxic compounds and conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1999063063A1 (en)	1998-06-03	1999-12-09	Northwestern University	Cellular proteins which mediate herpesvirus entry
US20030129685A1 (en) *	1998-10-28	2003-07-10	Jian Ni	12 human secreted proteins
DE19852800C1 (de)	1998-11-16	2000-04-13	Univ Albert Ludwigs Freiburg	Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
US20030022279A1 (en) *	1999-06-14	2003-01-30	Fraser Christopher C.	Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2002000677A1 (en)	2000-06-07	2002-01-03	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
MXPA03002479A (es)	2000-10-05	2004-05-24	Immunex Corp	Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
EP1402058A4 (en)	2001-06-05	2006-02-01	Exelixis Inc	DGKS AS P53 PATH MODIFICATORS AND METHOD OF USE
CA2449303C (en)	2001-06-06	2014-10-14	Regeneron Pharmaceuticals, Inc.	Method for targeting transcriptionally active loci
US20030084468A1 (en)	2001-09-05	2003-05-01	Economides Aris N.	Methods of expressing transgenes
CA2481507A1 (en) *	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20070224201A1 (en)	2002-10-02	2007-09-27	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
JPWO2005097204A1 (ja) *	2004-04-09	2008-02-28	武田薬品工業株式会社	癌の予防・治療剤

2007
- 2007-10-04 EP EP07829644A patent/EP2067791A4/en not_active Withdrawn
- 2007-10-04 MX MX2009003126A patent/MX2009003126A/es not_active Application Discontinuation
- 2007-10-04 CN CNA2007800371476A patent/CN101541834A/zh active Pending
- 2007-10-04 WO PCT/JP2007/069908 patent/WO2008044754A1/ja not_active Ceased
- 2007-10-04 US US12/444,382 patent/US20100008928A1/en not_active Abandoned
- 2007-10-04 KR KR1020097009036A patent/KR20090078339A/ko not_active Withdrawn
- 2007-10-04 AU AU2007307536A patent/AU2007307536A1/en not_active Abandoned
- 2007-10-04 CA CA002666249A patent/CA2666249A1/en not_active Abandoned
- 2007-10-04 PE PE2007001348A patent/PE20081456A1/es not_active Application Discontinuation
- 2007-10-04 RU RU2009117237/10A patent/RU2009117237A/ru not_active Application Discontinuation
- 2007-10-04 JP JP2008538759A patent/JPWO2008044754A1/ja not_active Withdrawn
- 2007-10-04 BR BRPI0717024-6A2A patent/BRPI0717024A2/pt not_active IP Right Cessation
- 2007-10-05 TW TW096137411A patent/TW200823235A/zh unknown
- 2007-10-05 CL CL200702879A patent/CL2007002879A1/es unknown
- 2007-10-09 AR ARP070104425A patent/AR063153A1/es unknown
2009
- 2009-03-03 IL IL197389A patent/IL197389A0/en unknown
- 2009-03-16 TN TN2009000090A patent/TN2009000090A1/fr unknown
- 2009-04-23 EC EC2009009276A patent/ECSP099276A/es unknown
- 2009-04-27 MA MA31823A patent/MA30816B1/fr unknown
- 2009-05-04 CO CO09044621A patent/CO6190538A2/es not_active Application Discontinuation
- 2009-05-05 NO NO20091783A patent/NO20091783L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JPWO2008044754A1 (ja)	2010-02-18
MA30816B1 (fr)	2009-10-01
BRPI0717024A2 (pt)	2014-03-11
WO2008044754A1 (en)	2008-04-17
EP2067791A1 (en)	2009-06-10
PE20081456A1 (es)	2008-11-27
IL197389A0 (en)	2011-08-01
NO20091783L (no)	2009-07-01
CO6190538A2 (es)	2010-08-19
EP2067791A4 (en)	2009-11-25
TN2009000090A1 (en)	2010-08-19
RU2009117237A (ru)	2010-11-20
MX2009003126A (es)	2009-04-06
CN101541834A (zh)	2009-09-23
US20100008928A1 (en)	2010-01-14
ECSP099276A (es)	2009-06-30
KR20090078339A (ko)	2009-07-17
AU2007307536A1 (en)	2008-04-17
AU2007307536A2 (en)	2009-04-30
AR063153A1 (es)	2008-12-30
TW200823235A (en)	2008-06-01
CA2666249A1 (en)	2008-04-17

Publication	Publication Date	Title
CL2007002879A1 (es)	2008-06-27	Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2007003794A1 (es)	2008-06-27	Anticuerpo anti-receptor del factor de crecimiento insulinico i (igf-ir); polinucleotido que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar cancer.
CL2008001334A1 (es)	2008-09-22	Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CL2008002319A1 (es)	2009-01-02	Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003212A1 (es)	2008-06-27	Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2008000029A1 (es)	2008-04-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2011000711A1 (es)	2012-07-20	Anticuerpo monoclonal que se une al receptor de regulacion negativa (nrr) de notch2; formulacion farmaceutica que lo comprende; y su uso para tratar una enfermedad maligna por celula b o melanoma.
HN2009000379A (es)	2012-01-30	Anticuerpo especifico prlr y sus usos
CL2008000754A1 (es)	2008-10-24	Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
CL2007000478A1 (es)	2008-03-14	Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
CL2015000028A1 (es)	2015-02-27	Inmunoconjugado que comprende un anticuerpo anti-cd79b unido a un agente citotóxico derivado de nemorrubicina; formulación farmacéutica que lo comprende; y uso para tratar cáncer cd79b positivo.
BRPI0812005A2 (pt)	2019-09-24	anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
IL197928A (en)	2014-02-27	A monoclonal antibody munched on steap-1, its immunoconjugates its uses
CL2008000197A1 (es)	2008-08-01	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008001656A1 (es)	2009-05-22	Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
HUE036477T2 (hu)	2018-07-30	Monoklonális anti-GT468 antitestek rák kezeléséhez
CL2008000793A1 (es)	2008-05-30	Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
BRPI0814420A2 (pt)	2015-11-17	composição, e, uso de álcool alcoxilado.
CL2008000794A1 (es)	2008-05-30	Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
CL2008001323A1 (es)	2009-05-29	Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BR112013013781A2 (pt)	2016-09-13	anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.